According to the European League Against Rheumatism (EULAR) guidelines for APS, high-risk profiles for APS is defined as a positive LA test, the presence of double (any combination of LA, aCL or aβ2GPI antibodies) or triple (all three subtypes) aPL positivity, or the presence of persistently high aPL titers (23). The gene discussed is ACLY; the disease is autoimmune polyendocrinopathy.